Lakewood-Amedex CEO Heads to H.C. Wainwright Global Investment Summit

During the three-day summit, Cooper will host a series of one-on-one sessions with institutional investors and prospective industry partners. These discussions aim to highlight the company’s recent operational progress and upcoming milestones for its proprietary Bisphosphocin platform. The firm focuses on addressing antibiotic-resistant bacterial threats, including MRSA and VRE, through its fast-acting therapeutic candidates. The presentation serves as a key touchpoint for the Sarasota-based company as it advances its clinical pipeline.